SCHEMBL15905899

SCHEMBL15905899

CS(=O)(=O)OCCn1c2c(c3ccccc31)C(C(=O)N1CCCCCC1)CCC2

nearest known ligand 0.73

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSPO P30536 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL414255 1.00 TSPO (0.50) TSPO
SCHEMBL414956 0.85 TSPO (0.64) TSPO
SCHEMBL415809 0.85 TSPO (0.64) TSPO
SCHEMBL15101781 0.85 TSPO (0.64) TSPO
SCHEMBL414797 0.85 TSPO (0.55) TSPO
SCHEMBL15101774 0.85 TSPO (0.64) TSPO
SCHEMBL419006 0.83 TSPO (0.48) TSPO
SCHEMBL15905900 0.83 TSPO (0.74) TSPO
SCHEMBL416453 0.80 TSPO (0.55) TSPO
SCHEMBL18902730 0.80 TSPO (0.50) TSPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411362-B1 Tricyclic indole derivatives as PBR ligands GE HEALTHCARE LTD (GB) 2017-05-31 EP disclosed
US-9220795-B2 Indole derivatives GE HEALTHCARE LIMITED (GB) 2015-12-29 US disclosed
US-20140364615-A1 INDOLE DERIVATIVES GE HEALTHCARE LIMITED (GB) 2014-12-11 US disclosed
US-8790619-B2 Indole derivatives GE HEALTHCARE LIMITED (GB) 2014-07-29 US disclosed
US-8790619-B2 Indole derivatives GE HEALTHCARE LIMITED (GB) 2014-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364615-A1 INDOLE DERIVATIVES IDO1, IDO2, INMT TSPO 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.